A Phase 3, Double-Blind, Placebo Controlled Multicenter Study to Determine the Efficacy and Safety of Luspatercept (ACE-536) in Adults With Transfusion Dependent Beta (β)-Thalassemia
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 17 Nov 2017
At a glance
- Drugs Luspatercept (Primary)
- Indications Beta-thalassaemia
- Focus Registrational; Therapeutic Use
- Acronyms BELIEVE
- Sponsors Celgene Corporation
- 09 Nov 2017 Planned End Date changed from 30 Apr 2019 to 7 Jun 2025.
- 09 Nov 2017 Planned primary completion date changed from 30 Sep 2018 to 24 Nov 2017.
- 01 Jun 2017 According to a Celgene Corporation media release, the company expects to report top-line results from the study in the middle of 2018.